Wells Fargo analyst Yanan Zhu initiated coverage of BeOne Medicines (ONC) with an Overweight rating and $400 price target The firm believes the company is well positioned in the $12B chronic lymphocytic leukemia market with “best-in-class options” for all patient segments. Wells believes BeOne has a “valuable and durable” core franchise with potential to grow beyond chronic lymphocytic leukemia, a market that is growing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines: FDA grants Priority Review to sBLA for tevimbra/ziihera combo
- BeOne Medicines price target lowered to $411 from $412 at Truist
- Buy Rating on BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones
- BeOne Medicines initiated with an Outperform at Wolfe Research
- BeOne Medicines Advances Combo Cancer Pill With Completed Phase 1 Bioavailability Study